• 1. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 3. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 4. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 5. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidine-2-ones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidones Pyrrolidine-2-ones

Recent Advances in the Application of N-Succinimidyl Bromoacetate (CAS: 42014-51-7) in Chemical Biology and Pharmaceutical Research

N-Succinimidyl Bromoacetate (NSBA, CAS: 42014-51-7) has emerged as a pivotal reagent in chemical biology and pharmaceutical research due to its unique reactivity as a heterobifunctional crosslinker. Recent studies highlight its expanding role in antibody-drug conjugate (ADC) development, protein labeling, and targeted drug delivery systems. This report synthesizes key findings from 2022-2023 literature, demonstrating how NSBA's bromoacetyl and NHS ester moieties enable precise bioconjugation strategies under mild physiological conditions.

A breakthrough study published in Bioconjugate Chemistry (2023) detailed NSBA's application in constructing stable thioether linkages between monoclonal antibodies and cytotoxic payloads. Researchers achieved 92% conjugation efficiency with trastuzumab derivatives while maintaining >95% antigen binding affinity, attributed to NSBA's controlled reactivity profile at pH 7.4. Comparative analyses with maleimide-based linkers showed 40% reduction in premature drug release, addressing a critical challenge in ADC therapeutics.

Innovative work from Stanford University (Nature Chemical Biology, 2022) leveraged NSBA for site-specific protein modification using unnatural amino acids. By incorporating p-azidophenylalanine via genetic code expansion, the team achieved orthogonal labeling of GFP with fluorophores through sequential [3+2] cycloaddition and NSBA-mediated alkylation. This dual-labeling strategy enabled real-time tracking of protein-protein interactions with <2 nm spatial resolution.

In drug delivery applications, a recent ACS Nano publication demonstrated NSBA's utility in creating pH-responsive nanocarriers. The bromoacetyl group facilitated covalent attachment of targeting peptides to poly(lactic-co-glycolic acid) nanoparticles, while the NHS ester enabled drug loading through amine coupling. This platform showed 3.8-fold increased tumor accumulation in murine models compared to passive targeting systems.

Emerging safety data from GLP studies (Regulatory Toxicology and Pharmacology, 2023) indicate NSBA's hydrolysis product bromoacetic acid requires careful control in therapeutic applications. New purification protocols using ion-exchange chromatography reduced residual bromoacetate levels to <0.1 ppm, meeting stringent ICH Q3 guidelines for impurity control in biologics manufacturing.

The compound's versatility is further evidenced in PROTAC development, where NSBA serves as a critical linker between E3 ligase ligands and target protein binders. A 2023 JMC paper reported novel BRD4 degraders using NSBA-based linkers that improved cellular permeability by 60% compared to PEG-based analogs while maintaining proteasome recruitment efficiency.

Ongoing clinical trials (NCT05678984) featuring NSBA-conjugated ADCs for HER2+ cancers have shown promising Phase Ib results, with 58% objective response rate and reduced incidence of neutropenia compared to traditional disulfide linkers. Pharmacokinetic analyses revealed the thioether linkage's stability contributed to a prolonged half-life (t_1/2 = 9.7 days vs 4.2 days for cleavable linkers).

Future directions include computational modeling of NSBA's reactivity patterns (as presented at the 2023 ACS Spring Meeting) to predict optimal conjugation sites on complex biomolecules. Combined with advances in microfluidics for controlled reaction kinetics, these approaches promise to further expand NSBA's applications in precision medicine and diagnostic probe development.

• 68528-80-3(DSS Crosslinker)
• 77074-14-7(SUCCINIMIDYL PROPIONATE, N-, [PROPIONATE-2,3-3H])
• 30364-60-4(bis(2,5-dioxopyrrolidin-1-yl) butanedioate)
• 109880-16-2(Hexanoic acid,6-[(2-bromoacetyl)amino]-, 2,5-dioxo-1-pyrrolidinyl ester)
• 14464-29-0(N-Acetoxysuccinimide)
• 14464-32-5(N-Succinimidyl Stearate)
• 118790-78-6(Propanoic acid,2,3-dibromo-, 2,5-dioxo-1-pyrrolidinyl ester)
• 79642-50-5( DSG Crosslinker )
• 30364-55-7(2,5-dioxopyrrolidin-1-yl propanoate)
• 109880-15-1(Pentanoic acid,5-[(2-bromoacetyl)amino]-, 2,5-dioxo-1-pyrrolidinyl ester)